Four Dow Movers to Follow (AKS, ALU, CTIC, CSCO)

Los Angelas, CA -- (SBWIRE) -- 01/23/2013 -- AK Steel Holding Corporation (NYSE:AKS) rose by 1.08% to a market valuation of $4.67 per share, after the Company announced that it will be raising the current spot market base prices for all of its carbon flat-rolled steel products by $40 per ton. This will be effective immediately with all of its new orders. The Company is dealing with weak steel demand, oversupply within the industry and pricing pressure. Lower steel pricing affected the Company’s bottom line negatively in the third quarter for the year 2012. AK Steel will be releasing its fourth quarter results on January 29, 2013.

Will AKS Continue To Rise For The Long Run? Find Out More Here

Alcatel Lucent SA (NYSE:ALU) surged upwards by 2.42% to $1.69 per share, rising above its opening market valuation of $1.67 per share. ALU currently has an RSI of 65.56, revealing a slightly overbought levels for the Company’s shares. ALU’s MACD has currently leveled out.Alcatel Lucent has revealed that it has received an 8-year contract from the India-based Reliance Communications to manage its fixed and mobile networks in the eastern and southern regions of India. The contract is valued at $1 billion and is put in place to cut costs and improve the efficiencies for Reliance Communications. The contract states that approximately 15% of Reliance Communications employees will be employed by Alcatel. In par with this agreement, the company will primarily manage networks of big telecom companies, but just 25% of these contracts will be profitable, putting pressure upon its margins. The Company plans to exit these contracts by the end of the fiscal 2013.

Receive The Latest Free Trend Analysis Report On ALU Here

Cell Therapeutics Inc. (NASDAQ:CTIC) surged 9.03% to $1.57 per share for Tuesday’s trading session. Cell Therapeutics, which opened the day at $1.50 per share, experienced a slight decline of 0.64% to $1.56 per share during the after hours trading session. CTIC’s MACD has taken a slight turn upwards, revealing an increased cash flow towards the Company’s equity. Cell Therapeutics Inc. announced that the Company will be providing a live audio and slide webcast of its analyst and investor meeting to be held on January 23 in New York. Expert speakers will be focusing upon advancements in treatment using JAK inhibitors and any existing challenges in the treatment of myelofibrosis patients. Cell Therapeutics Inc. engages in the acquisition, development, and commercializing of drugs used in the treatment of cancer. The Company works with Chroma Therapeutics Ltd. in the development of Tosedostat, which is an oral aminopeptidase inhibitor. Cell Therapeutics, founded in 1991, is based in Seattle, Washington.

Should Investor Book Profit Or Hold CTIC This Range: Check Out Here

Cisco Systems (NASDAQ:CSCO) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $22.00 price target on the stock. Zacks’ analyst wrote, “Cisco Systems is the leading provider of IP-based networking and other products. The company’s first-quarter earnings beat the Zacks Consensus Estimate, with forward guidance for the next quarter coming in line with expectations. We think that despite a sluggish macro-environment and increasing competition, it is hard to ignore the company’s market position, innovative prowess, product range, growth initiatives and dividend payout. Additionally, all its end markets are likely to see very strong growth over the next few years. Given these factors and the reasonable valuation, we are reiterating our Neutral recommendation on CSCO shares.

Should Investor Book Profit Or Hold CSCO This Range: Check Out Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com